Filing Details
- Accession Number:
- 0001209191-15-060141
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-08 16:53:58
- Reporting Period:
- 2015-07-06
- Filing Date:
- 2015-07-08
- Accepted Time:
- 2015-07-08 16:53:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1577034 | J Robert Gould | C/O Epizyme, Inc. 400 Technology Square Cambridge MA 02139 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2015-07-06 | 60,000 | $0.51 | 60,000 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2015-07-06 | 44,858 | $23.07 | 15,142 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2015-07-06 | 15,142 | $23.64 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2015-07-06 | 60,000 | $0.00 | 60,000 | $0.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 507,223 | 2020-03-17 | No | 4 | M | Direct |
Footnotes
- The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.58 per share to $23.57 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.58 per share to $23.89 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This option was granted on March 18, 2010 with respect to 870,557 shares of Common Stock, with 25% vesting on March 18, 2011 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Billionaire Hedge Funds
